||
Cardiovascular disorders related to HMGB1 over-expression
Bio3 Research has entered into a
strategic alliance with Syngen Inc.
(CA/USA) and Protelix Inc. (CA/USA)
for the development, under their technological platforms, of SiRNA HMGB1
specific and Mimic Abs anti-HMGB1 in cardiovascular field (e.g. Arterial
Stenosis, Restenosis and Atherosclerotic Plaque progression inhibition).
SiRNA (Small Interfering RNA) HMGB1 specific have
been designed to inhibit the expression of the protein HMGB1 at cell level without
transfection. In vitro tests (also with optimized/purified SiRNA) have been
successfully performed to verify SiRNA specificity against HMGB1.A lead has been selected to perform
Proof of Concept in animals in 2010.
Mimic-Abs HMGB1-specific have
been selected for further development by utilizing ProtElix pioneering
technology which has the advantage to accelerate
the development of new therapeutic tools with better tissue penetration, expected
lower production costs and longer shelf-life. Optimization ofAbs Mimic HMGB1 specific has already been
performed and the clone R2F8 will soon be tested in animals.PEG-R2F8 has been selected for preclinical
development for chronic treatments. Animal tests are expected to start by 3Q/4Q
2010.
Bio3 News...
Bio3 Research has recently been granted from USPTO the
US
patent # 10/471,641 which claims the use of HMGB1 inhibitors and antagonists for
the treatment of Cardiovascular Disorders…
